Selective antagonism of cJun for cancer therapy. (2020)
Attributed to:
Irreversibly Silencing Oncogenic Master-regulator cMyc Using Library-derived Electrophilic Helical Peptides
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s13046-020-01686-9
PubMed Identifier: 32917236
Publication URI: http://europepmc.org/abstract/MED/32917236
Type: Journal Article/Review
Volume: 39
Parent Publication: Journal of experimental & clinical cancer research : CR
Issue: 1
ISSN: 0392-9078